LOVIDRA in diabetic women to assess impact on quality of life

The Department of Emerging Pathologies and Continuity of Care, U.O.C. of Internal Medicine at the University Polyclinic of Palermo, under the direction of Prof. Citarella, has been conducting a clinical study on LOVIDRA for several months.This groundbreaking research for the first time evaluates, “the impact of a high-quality, ecoderma compatible topical product; which is used as a daily cosmetic, on vaginal dryness and quality of life in diabetic women or those with insulin resistance who exhibit symptoms of vulvovaginal atrophy and dystrophy” (cf. Study Rationale).

LOVIDRA is an intimate serum designed for vulvovaginal application. It is composed of three molecular weights (high, medium, and very low) of Hyaluronic Acid, Rice Bran Oil rich in Vitamin E, and pure Tocopherol.

Numerous studies have shown that in women with type 2 diabetes, the prevalence of sexual dysfunction due to vulvovaginal atrophy is approximately 70%.

Given the high prevalence of sexual dysfunction in women with type 2 diabetes or insulin resistance, appropriate methods should be embraced.

This open-label, two-arm, prospective study involves administering LOVIDRA to the intervention group. This group consists of women with diabetes, impaired glucose tolerance, and/or insulin resistance who exhibit symptoms of vulvovaginal atrophy and dystrophy. Participants are from the Diabetes and Cardiovascular Prevention Clinic at the UOC of Internal Medicine.

Eligible women will apply LOVIDRA gel morning and evening for a duration of 3 months.

The aim is to assess the effectiveness of LOVIDRA on vaginal dryness and quality of life. Moreover the study seeks to determine if alleviating these symptoms and improving sexual dysfunction positively impacts cardiovascular outcomes (cf. Study Rationale).